129 related articles for article (PubMed ID: 8741259)
1. Contrast-enhanced MRI with gadodiamide injection in rat disease models.
Yamada K; Miyahara K; Sato H; Nakayama W; Sato M; Hirose T; Kato H; Ikehira H; Tateno Y; Sugihara H; Furuhama K
J Vet Med Sci; 1996 Apr; 58(4):291-5. PubMed ID: 8741259
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced MRI with gadodiamide injection in rabbit carcinoma models.
Yamada K; Jinbo T; Miyahara K; Sato M; Hirose T; Kato H; Tateno Y; Ikehira H; Sugihara H; Furuhama K
J Vet Med Sci; 1996 May; 58(5):389-96. PubMed ID: 8741596
[TBL] [Abstract][Full Text] [Related]
3. Neurotolerability of contrast agents in rats with brain ischemia induced by transient middle cerebral artery occlusion: EEG evaluation.
Frigeni V; Miragoli L; Grotti A; Lorusso V
Invest Radiol; 2001 Jan; 36(1):1-8. PubMed ID: 11176255
[TBL] [Abstract][Full Text] [Related]
4. [Use of Omniscan (gadodiamide) in magnetic resonance studies of the central nervous system (results of a multicenter study)].
Sinitsyn VE; Kornienko VN; Nikitin VG; Pronin IN; Ternovoĭ SK; Tiutin LA; Iakobson MG
Vestn Rentgenol Radiol; 1995; (4):5-11. PubMed ID: 8571538
[TBL] [Abstract][Full Text] [Related]
5. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
6. Ultrafast contrast enhanced magnetic resonance imaging of congenital hydronephrosis in a rat model.
Fichtner J; Spielman D; Herfkens R; Boineau FG; Lewy JE; Shortliffe LM
J Urol; 1994 Aug; 152(2 Pt 2):682-7. PubMed ID: 8021995
[TBL] [Abstract][Full Text] [Related]
7. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
Akeson P; Larsson EM; Kristoffersen DT; Jonsson E; Holtås S
Acta Radiol; 1995 May; 36(3):300-6. PubMed ID: 7742127
[TBL] [Abstract][Full Text] [Related]
8. Combined perfusion and diffusion-weighted magnetic resonance imaging in a rat model of reversible middle cerebral artery occlusion.
Müller TB; Haraldseth O; Jones RA; Sebastiani G; Godtliebsen F; Lindboe CF; Unsgård G
Stroke; 1995 Mar; 26(3):451-7; discussion 457-8. PubMed ID: 7886724
[TBL] [Abstract][Full Text] [Related]
9. MR imaging of pituitary region lesions with gadodiamide injection.
Hald JK; Skalpe IO; Bakke SJ; Nakstad PH
Acta Radiol; 1994 Jan; 35(1):65-9. PubMed ID: 8305277
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study.
Svaland MG; Christensen T; Lundorf E
Acta Radiol; 1994 Jul; 35(4):396-9. PubMed ID: 8011392
[TBL] [Abstract][Full Text] [Related]
11. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging.
Normann PT; Hals PA
Eur J Drug Metab Pharmacokinet; 1995; 20(4):307-13. PubMed ID: 8983938
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.
Morelli JN; Runge VM; Vu L; Loynachan AT; Attenberger UI
Invest Radiol; 2010 Dec; 45(12):810-8. PubMed ID: 20856127
[TBL] [Abstract][Full Text] [Related]
13. MR imaging of the myocardium using nonionic contrast medium: signal-intensity changes in patients with subacute myocardial infarction.
Dulce MC; Duerinckx AJ; Hartiala J; Caputo GR; O'Sullivan M; Cheitlin MD; Higgins CB
AJR Am J Roentgenol; 1993 May; 160(5):963-70. PubMed ID: 8470611
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of the tolerability of gadodiamide, a new nonionic contrast agent in MRI of the central nervous system].
Aslanian V; Lemaignen H; Bunouf P; Schiratti M; Lambrechts M; Lundby B; Borseth A; Svaland M
J Radiol; 1995 Jul; 76(7):431-4. PubMed ID: 7473377
[TBL] [Abstract][Full Text] [Related]
15. Brain lesion contrast in MR imaging. Dependence on field strength and concentration of gadodiamide injection in patients and phantoms.
Akeson P; Vikhoff B; Ståhlberg F; Holtås S
Acta Radiol; 1997 Jan; 38(1):14-8. PubMed ID: 9059395
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of gadodiamide injection in paediatric MR imaging.
Hanquinet S; Christophe C; Greef DD; Gordon P; Perlmutter N
Pediatr Radiol; 1996 Nov; 26(11):806-10. PubMed ID: 8929382
[TBL] [Abstract][Full Text] [Related]
17. Detection of reperfused ischemia of the rat intestine: value of magnetic resonance imaging with small-molecular-weight dysprosium and gadolinium chelates.
Van Beers BE; Goudemant JF; Oksendal A; Jamart J; Delos M; Thiran JP; Demeure R; Pringot J; Maldague B
Acad Radiol; 1997 Jan; 4(1):35-42. PubMed ID: 9040868
[TBL] [Abstract][Full Text] [Related]
18. Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI.
Unger EC; MacDougall P; Cullis P; Tilcock C
Magn Reson Imaging; 1989; 7(4):417-23. PubMed ID: 2811620
[TBL] [Abstract][Full Text] [Related]
19. Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5 T.
Demaerel P; Marchal G; Wilms G; Van Calenbergh F; De Greef D; Børseth A; Baert AL
Neuroradiology; 1994 Jul; 36(5):355-9. PubMed ID: 7936174
[TBL] [Abstract][Full Text] [Related]
20. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium.
Normann PT; Frøysa A; Svaland M
Scand J Clin Lab Invest; 1995 Aug; 55(5):421-6. PubMed ID: 8545600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
